United Lige Completes RMB 200 Million Series B Financing Led by Jinpu Health Services Industry Investment Fund
VCBeat (WeChat: vcbeat) has learned that on June 15, United LiGe, a leading medical aesthetics group in China, announced the completion of its RMB 200 million Series B financing round. The round was led by Jinpu Health Service Industry Investment Fund, with iCapital serving as the exclusive financial advisor.
This marks BCC’s second round of financing since it secured Series A investment from Founder & Han Investment Fund and China Equity Capital in early 2016. Following this round, BCC will accelerate the nationwide expansion of its medical aesthetics network, aiming to become China’s leading entrepreneurial platform for medical aesthetics physicians.
Founded in 2013 by Li Bin, BTL Medical Group has become one of the most influential chain brands in China’s medical aesthetics industry within just four years.
It has been learned that United Liger currently invests in and operates more than 30 medical aesthetic institutions across over 10 cities in China. The company expects to expand its network to cover more than 50 medical aesthetic institutions by 2017, including a flagship central hospital with an area of over 10,000 square meters soon to open in Beijing. This newly opened central hospital will become a specialized medical aesthetic hospital boasting strong medical capabilities and integrating medical care, education, and research.
Medical aesthetics employs medical procedures to address patients’ desires for enhanced appearance. Therefore, the core competitive advantage of medical aesthetics lies precisely in its “medical” nature; it is the physician’s clinical practice that constitutes the central value accepted and recognized by consumers. Returning the medical aesthetics industry to its fundamental medical essence is the top priority for promoting the healthy development of the entire sector.
United LiGe has always advocated “returning to the essence of medicine,” reshaping the trust relationship between patients and doctors, and truly enhancing patients’ medical experience and the quality of healthcare services.
Furthermore, as physicians become increasingly aware of their professional value, many are choosing to redefine their roles within the medical aesthetics workflow. Union Beauty is China’s first platform dedicated to supporting outstanding physicians in launching their own ventures in the medical aesthetics industry. By partnering with independently practicing medical aesthetics physicians to establish clinical institutions, Union Beauty provides comprehensive resource support, thereby delivering higher-quality medical aesthetic services to patients and ultimately fostering a virtuous cycle.
Regarding this investment, Li Bin, Founder and Chairman of BCCG (Beijing United Beauty), stated: “The mission of BCCG is to restore the due respect for medical aesthetics practitioners, especially physicians, and to enable more patients to access high-quality and safe medical aesthetic services. Following this round of financing, BCCG will continue to uphold its core philosophy of respecting physicians and returning to the essence of medical care, by building a platform that empowers more medical aesthetic physicians to pursue independent entrepreneurial ventures.”
Fan Yin, Managing Partner of Jinpu Health Service Industry Investment Fund, the lead investor in this round, stated, “We are honored to participate in Beauty United’s current financing round. The medical aesthetics sector is one of the fastest-growing segments within the healthcare services industry. Currently, there is a shortage in China of private medical aesthetics chains like Beauty United that boast innovative business models, strong brand influence, and rapid scalability. We also look forward to working with Beauty United to establish industry standards and foster healthier, more robust growth in the private medical aesthetics sector.”
About the Jinpu Health Service Industry Investment Fund:
Jinpu Health Service Industry Investment Fund focuses on medical services as its primary investment direction, specializing in the investment, M&A, and integration of China’s domestic medical services industry. It is committed to becoming the most dedicated and influential professional investment institution in China’s healthcare services sector.
The Fund’s primary investors include government-guided funds, domestically listed companies in the healthcare sector, large private investment holding companies, and state-owned investment groups. To date, the Fund has invested in dozens of outstanding domestic healthcare service enterprises.
About China Renaissance Capital:
Founded in 2000, China Renaissance is a leading private investment bank in China, focusing on the new economy and the restructuring and upgrading of traditional industries. In October 2016, it announced the acquisition of the U.S. securities firm Siemer & Associates, thereby securing a U.S. securities business license. China Renaissance was the first investment bank to provide institutionalized coverage of the A-share market and domestic primary market investment institutions.
The firm currently maintains offices in Beijing, Shanghai, and Los Angeles. Its core business lines include mergers and acquisitions (M&A), private equity financing, and asset management. Between 2015 and 2016, the investment banking team successfully completed nearly 80 financing and M&A transactions, with a cumulative transaction value exceeding RMB 90 billion. Beyond its investment banking services, Capital Edge is building a distinctive asset management platform that fully leverages the synergies of its investment banking capabilities.